数据之源，洞见之始

FLT3 signaling in disease

Kazi JU, Rönnstrand L. FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. Physiol Rev. 2019 Jul 01;99(3):1433–66. doi: 10.1152/physrev.00029.2018. PMID: 31066629.; Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019 Jan 16;33(2):299–312. doi: 10.1038/s41375-018-0357-9.; Klug LR, Kent JD, Heinrich MC. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. Pharmacol Ther. 2018 Nov;191():123–34. doi: 10.1016/j.pharmthera.2018.06.016. PMID: 29964125.; Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, Dun MD. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. Int J Mol Sci. 2018 Oct 16;19(10). PMID: 30332834; PMCID: PMC6214138.; Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004 Jan 01;103(1):267–74. doi: 10.1182/blood-2003-06-1969. PMID: 12969963.